Technology
Health
Biotechnology

Five Prime Therapeutics

$13.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.54 (-3.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FPRX and other stocks, options, ETFs, and crypto commission-free!

About

Five Prime Therapeutics, Inc. Common Stock, also called Five Prime Therapeutics, is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. Read More The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Employees
209
Headquarters
South San Francisco, California
Founded
2001
Market Cap
472.89M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
363.76K
High Today
$13.59
Low Today
$13.06
Open Price
$13.54
Volume
200.27K
52 Week High
$19.95
52 Week Low
$7.84

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2013 IPO
US

News

BusinessWireMar 5

Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Wednesday, March 13, 2019 at 8:40am ET. The presentation will be webcast and may be accessed at the “Events & Presentations” section of th...

7
Seeking AlphaFeb 26

Five Prime Therapeutics, Inc. (FPRX) CEO Aron Knickerbocker on Q4 2018 Results - Earnings Call Transcript

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Martin Forrest - Vice President of Investor Relations and Corporate Communications Aron Knickerbocker - Chief Executive Officer Helen Collins - Chief Medical Officer Bryan Irving - Chief Scientific Officer David Smith - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Kennen MacKay - RBC Capital Markets Operator Welcome to the Five Pri...

67
The Motley FoolFeb 26

Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript

Five Prime Therapeutics Inc (NASDAQ:FPRX) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Five Prime Therapeutics Fourth Quarter and Fiscal Year 2018 Earnings Call. As a reminder, this conference call is being recorded. I'd now like to introduce your host for today's conference, Martin Forrest, Vice President, Investor Relations and Corporate Communications. You may begin. Martin Forrest -...

1

Earnings

-$1.58
-$1.24
-$0.89
-$0.55
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.